Page last updated: 2024-08-21

quinazolines and a-Synucleinopathies

quinazolines has been researched along with a-Synucleinopathies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cai, E; Del Cid Pellitero, E; Durcan, TM; Fon, EA; Larroquette, F; Luo, W; Soubannier, V; Tavassoly, O; Thomas, RA	1

Other Studies

1 other study(ies) available for quinazolines and a-Synucleinopathies

Article	Year
Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:2 Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinazolines; RNA, Small Interfering; Synucleinopathies	2021

Article

Year

Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:2

Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinazolines; RNA, Small Interfering; Synucleinopathies

2021